Skip to main content

Table 3 Prevalence of demographic and clinical characteristics and 95% confidence intervals in youth with opioid use disorder (OUD) with and without documented treatment with medications for OUD (N = 2131)

From: Receipt of medications for opioid use disorder among youth engaged in primary care: data from 6 health systems

  Medication treatmenta (n = 752)
%, (95% CI)
No treatment (n = 1379)
%, (95% CI)
Female 38 (35, 42) 42 (39, 45)
Race/ethnicity
 Hispanic 8.8 (6.9, 11) 8.7 (7.3, 10)
 Caucasian 79 (76, 82) 76 (74, 78)
 Black/African American 1.9 (1.0, 3.1) 3.8 (2.9, 5)
 Asian 1.2 (0.5, 2.3) 2.0 (1.4, 2.9)
 NA/AN 0.5 (0.1, 1.4) 0.7 (0.3, 1.3)
 Hawaiian/Pacific Islander 0.8 (0.3, 1.7) 0.1 (0.02, 0.5)
 Multiracial 3.9 (2.6, 5.5) 5.1 (4, 6.4)
 Other 0.8 (0.3, 1.7) 0.9 (0.5, 1.6)
 Unknown 3.1 (1.9, 4.6) 2.7 (1.9, 3.7)
Insuranceb
 Medicare 11 (8.7, 13) 13 (11, 16)
 Commercial 85 (83, 88) 81 (78, 83)
 State subsidized 0 (0, 0.5) 0.2 (0.02, 0.7)
 Uninsured 3.8 (2.5, 5.4) 5.6 (4.3, 7.2)
Tobacco UD 56 (52, 59) 52 (50, 55)
Alcohol UD 21 (18, 24) 26 (24, 29)
Cannabis UD 34 (31, 38) 32 (30, 35)
Stimulant UD 30 (26, 33) 27 (25, 29)
OD 3.3 (2.2, 4.9) 3.7 (2.8, 4.8)
Depression 36 (32, 39) 48 (45, 50)
Anxiety 42 (38, 45) 50 (48, 53)
Serious mental illnessc 6.9 (5.2, 9.0) 12 (10, 14)
ADD 11 (9.1, 14) 14 (12, 16)
Eating disorder 0.8 (0.3, 1.7) 2.5 (1.8, 3.5)
  1. NA/AN Native American/Alaskan American, OD opioid overdose, UD use disorders, ADD attention deficit disorder
  2. Bolded results are significant at p < 0.05
  3. aOne or more prescriptions or procedure codes for buprenorphine and/or naltrexone in the fiscal year of index visit
  4. bExcludes one health system with missing insurance data
  5. c Serious mental illness defined as schizophrenia and bipoloar disorder